Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 401–500 of 1,000
Mathematical Modeling, Analysis, and Simulation of Tumor Dynamics with Drug Interventions
Unni, P., & Seshaiyer, P. (2019) · Computational and Mathematical Methods in Medicine · doi:10.1155/2019/4079298 · Cited by 59
“We begin with modeling tumor cells T which are assumed to have a proliferation rate that can be modeled by a logistic growth law aT(1 − bT), with parameters a and b denoting the per capita growth rates and reciprocal carrying capacities of the tumor cells [8, 9, 26].”
MethodAnalysis of a stochastic tumor-immune model with regime switching and impulsive perturbations
Deng, Y., & Liu, M. (2019) · Applied Mathematical Modelling · doi:10.1016/j.apm.2019.10.010 · Cited by 61
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
Sayitoğlu, E. C., Georgoudaki, A., Chrobok, M., Özkazanç, D., Josey, B. J., Arif, M., Kusser, K. L., Hartman, M., Chinn, T. M., Potens, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00040 · Cited by 61
Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I
Draghi, M., Yawata, N., Gleimer, M., Yawata, M., Valiante, N. M., & Parham, P. (2004) · Blood · doi:10.1182/blood-2004-08-3174 · Cited by 70
Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy
Jiang, J., Huang, Y., Zeng, Z., & Zhao, C. (2023) · ACS Nano · doi:10.1021/acsnano.2c07607 · Cited by 59
NK Cell Receptors as Tools in Cancer Immunotherapy
Sentman, C. L., Barber, M. A., Barber, A., & Zhang, T. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95007-6 · Cited by 61
“It has been reported that tumors that express NKG2D ligands are more easily rejected than tumors that lack these ligands (Cerwenka et al., 2001; Diefenbach et al., 2001, 2003; Hayakawa et al., 2002; Westwood et al., 2004).”
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies
Tanaka, J., & Miller, J. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100678 · Cited by 62
Stress, NK Receptors, and Immune Surveillance
Pardoll, D. M. (2001) · Science · doi:10.1126/science.1066284 · Cited by 65
Natural killer cell‐mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions
Backström, E., Chambers, B. J., Ho, E. L., Naidenko, O. V., Mariotti, R., Fremont, D. H., Yokoyama, W. M., Kristensson, K., & Ljunggren, H. (2003) · European Journal of Immunology · doi:10.1002/immu.200390012 · Cited by 55
NKG2D receptor–mediated NK cell function is regulated by inhibitory Ly49 receptors
Regunathan, J., Chen, Y., Wang, D., & Malarkannan, S. (2004) · Blood · doi:10.1182/blood-2004-03-1075 · Cited by 62
Spada, R., Rojas, J. M., Pérez-Yagüe, S., Mulens‐Arias, V., Cannata‐Ortiz, P., Bragado, R., & Barber, D. F. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0714-326r · Cited by 57
“In accordance with the reported correlation of site-specific expression of NKG2D ligands with specific NK cell accumulation at the same site [38, 39], we observed that the expression NKG2D ligands in SLE-prone mouse kidneys correlated with an increase in NK cell infiltration as the disease progressed.”
BackgroundImportance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell
Bae, D. S., Hwang, Y. K., & Lee, J. K. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.04.011 · Cited by 59
Tuning cancer fate: the unremitting role of host immunity
Calì, B., Molon, B., & Viola, A. (2017) · Open Biology · doi:10.1098/rsob.170006 · Cited by 62
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 59
Haspels, H. N., Rahman, M. A., Joseph, J. V., Navarro, A. G., & Chekenya, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01345 · Cited by 59
“, MHC chain-related antigens (MICA/B) and the UL16-binding proteins (ULBPs) (27, 28), as well as natural cytotoxicity receptors (NCRs) NKp30 and DNAM-1 that recognize, respectively, B7-H6 and CD112.”
BackgroundCurrent status of haploidentical stem cell transplantation
Dey, B. R., & Spitzer, T. R. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06300.x · Cited by 58
“NK cells also possess activating receptors, most notably NKG2D and NKp46, which can trigger NK-cell alloreactivity when they are engaged by appropriate antigens on virally infected cells and tumour cells (Bauer et al, 1999; Diefenbach et al, 2001; Mandelboim et al, 2001; Lanier, 2005).”
BackgroundTNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors
Maccalli, C., Scaramuzza, S., & Parmiani, G. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0635-x · Cited by 58
“Ectopic expression of NKG2D ligands causes rejection of tumor cells by NK and cytotoxic (CTL) T cells in syngeneic mice [8, 15], showing the relevance of NKG2D signal-”
BackgroundPan, P., Gu, P., Li, Q., Xu, D., Weber, K. J., & Chen, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4779 · Cited by 56
Capitalizing on the Immunogenicity of Dying Tumor Cells
Fonseca, C., & Dranoff, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2245 · Cited by 63
Wu, J. D., Atteridge, C. L., Wang, X., Seya, T., & Plymate, S. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1305 · Cited by 58
Andresen, L. O., Jensen, H., Pedersen, M. T., Hansen, K. A., & Skov, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8235 · Cited by 55
“We and others have previously shown that cancer cells can be stimulated to express the NKG2D-ligands MHC class I chain-related protein A (MICA)/B after exposure to histone deacetylase (HDAC)-inhibitors (HDAC-i)5 (6, 7), an occurrence that was not observed in healthy cells.”
BackgroundInfluentialNolting, A., Dugast, A., Rihn, S. J., Luteijn, R. D., Carrington, M. N., Kane, K., Jost, S., Tóth, I., Nagami, E. H., Faetkenheuer, G., et al. (2010) · Virology · doi:10.1016/j.virol.2010.05.014 · Cited by 54
“The activating signal triggered by the NKG2D-ligand-complex is one of the few dominant activating signals, as it can override inhibitory signals (Diefenbach et al., 2001).”
InfluentialGowen, B. G., Chim, B., Marceau, C. D., Greene, T. T., Burr, P., Gonzalez, J. R., Hesser, C. R., Dietzen, P. A., Russell, T. A., Iannello, A., et al. (2015) · eLife · doi:10.7554/elife.08474 · Cited by 58
“Previously published evidence demonstrated that greater NK-dependent tumor elimination occurs with increasing amounts of cell surface NKG2D ligand (Diefenbach et al., 2001), consistent with the ‘threat-level’ hypothesis.”
ResultSelf-citationRubio, M., Saito, T. I., Kattleman, K., Zhao, G., Buchli, J., & Sykes, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.665 · Cited by 54
“Consistent with this hypothesis, A20 expresses Fas and retinoic acid early inducible-1, which have been involved in antitumor responses in mice (28, 32).”
BackgroundNausch, N., Florin, L., Hartenstein, B., Angel, P. E., Schorpp‐Kistner, M., & Cerwenka, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.7 · Cited by 62
“In vivo, however, ectopic expression of NKG2D ligands on tumor cells leads to NK cellmediated tumor rejection even in the presence of self-MHC class I (10, 11).”
BackgroundDendritic cells and innate defense against tumor cells
Ullrich, E., Menard, C., Flament, C., Terme, M., Mignot, G., Bonmort, M., Plumas, J., Chaperot, L., Chaput, N., & Zitvogel, L. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.009 · Cited by 57
Dupont, B., & Hsu, K. C. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.013 · Cited by 54
Assessment of the humoral immune response to cancer
Murphy, M., O’Leary, J. J., & Cahill, D. J. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.01.021 · Cited by 59
“[8] Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.”
BackgroundBlockade of NKG2D signaling prevents the development of murine CD4+T cell-mediated colitis
Ito, Y., Kanai∥, T., Totsuka, T., Okamoto, R., Tsuchiya, K., Nemoto, Y., Yoshioka, A., Tomita, T., Nagaishi, T., Sakamoto, N., et al. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00286.2007 · Cited by 53
“It has been demonstrated that the activation via NKG2D receptor can enhance negative signals by MHC class I-specific NK cell inhibitory receptors (9, 15).”
BackgroundInhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model
Kong, L.-Y., Gelbard, A. H., Wei, J., Reina-Ortiz, C., Wang, Y., Yang, E. C. C., Hailemichael, Y., Fokt, I., Jayakumar, A., Qiao, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0279 · Cited by 56
“The B16 cells expressed the MHC I, Rae1, H60, and CD155, indicating that they would be capable of triggering NK cytotoxic responses, resulting in tumor clearance similar to findings in a previous report (45), but treatment did not alter the expression of the ligands.”
ResultCellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
Eagle, R. A., Flack, G., Warford, A., Martínez-Borra, J., Jafferji, I., Traherne, J. A., Ohashi, M., Boyle, L. H., Barrow, A. D., Caillat‐Zucman, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004503 · Cited by 59
“In mice, the ectopic expression of NKG2D ligands mediates immune responses to transplanted tumours[18,19].”
BackgroundHolmes, T. D., El-Sherbiny, Y. M., Davison, A., Clough, S. L., Blair, G. E., & Cook, G. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000951 · Cited by 52
Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells
Vyas, M., Requesens, M., Nguyen, T. H., Peigney, D., Azin, M., & Demehri, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098445 · Cited by 52
“Likewise, we and others have utilized metastatic models to demonstrate that NK cells are critical for curbing the spread of intravenously injected cancer cells to distant organs (17, 21).”
BackgroundKarimi, M. A., Bryson, J. L., Richman, L. P., Fesnak, A. D., Leichner, T. M., Satake, A., Vonderheide, R. H., Raulet, D. H., Reshef, R., & Kambayashi, T. (2015) · Blood · doi:10.1182/blood-2015-02-629006 · Cited by 52
Self-citationTokuyama, M., Lorin, C., Delebecque, F., Jung, H., Raulet, D. H., & Coscoy, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002265 · Cited by 51
“Clearance in vivo is mediated by NK cells and in some cases CD8 T cells, despite expression of inhibitory MHC-I molecules in some tumor cells [6,24].”
BackgroundSelf-citationWilkie, K. P., & Hahnfeldt, P. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0291-4 · Cited by 54
Benitez, A. C., Dai, Z., Mann, H. H., Reeves, R. S., Margineantu, D. H., Gooley, T. A., Groh, V., & Spies, T. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018603108 · Cited by 54
Pro‐inflammatory role of natural killer cells in the development of allergic airway disease
Mathias, C. B., Guernsey, L. A., Zammit, D. J., Brammer, C., Wu, C. A., Thrall, R. S., & Aguila, H. L. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12271 · Cited by 51
Chen, Y., Chen, B., Yang, T., Xiao, W., Qian, L., Ding, Y., Ming-chun, J., Ge, X., & Gong, W. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.81 · Cited by 52
Diversification of human NK cells: Lessons from deep profiling
Wilk, A. J., & Blish, C. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.6ri0917-390r · Cited by 54
A comprehensive expression landscape of RNA-binding proteins (RBPs) across 16 human cancer types
Zhang, B., Babu, K. R., Lim, C. Y., Kwok, Z. H., Li, J., Zhou, S., Yang, H. H., & Tay, Y. (2019) · RNA Biology · doi:10.1080/15476286.2019.1673657 · Cited by 58
IL-17D: A Less Studied Cytokine of IL-17 Family
Liu, X., Sun, S., & Liu, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508255 · Cited by 51
Imbert, M., Scoazec, J., Mary, J., Jouzult, H., Rochant, H., & Sultan, C. (1989) · PubMed · Cited by 68
Non‐classical major histocompatibility complex proteins as determinants of tumour immunosurveillance
Gomes, A. Q., Correia, D. V., & Silva‐Santos, B. (2007) · EMBO Reports · doi:10.1038/sj.embor.7401090 · Cited by 59
Tumor cell recognition by the NK cell activating receptor NKG2D
Bryceson, Y. T., & Ljunggren, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838833 · Cited by 53
Tamaki, S., Sanefuzi, N., Kawakami, M., Aoki, K., Imai, Y., Yamanaka, Y., Yamamoto, K., Ishitani, A., Hatake, K., & Kirita, T. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.01.010 · Cited by 52
Chen, Y., Lin, G., Guo, Z., Zhou, Z., He, Z., & Ye, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069044 · Cited by 50
“Indeed, ectopic expression of NKG2D ligands by tumors induces perforin-dependent strong NK and cytotoxic T lymphocyte (CTL) responses in vivo [13,29].”
BackgroundNKG2D: A versatile player in the immune system
Jelenčić, V., Lenartić, M., Wensveen, F. M., & Polić, B. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.04.006 · Cited by 51
Choucair, K., Duff, J. R., Cassidy, C. S., Albrethsen, M., Kelso, J. D., Lenhard, A., Staats, H., Patel, R., Brunicardi, F. C., Dworkin, L. D., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0116 · Cited by 51
Regunathan, J., Chen, Y., Kutlesa, S., Dai, X., Bai, L., Wen, R., Wang, D., & Malarkannan, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5365 · Cited by 49
“Earlier studies illustrated that ectopic expression of NKG2D ligands, H60 molecules, on autologous tumor cells can render them susceptible to NK-mediated cytotoxicity through NKG2D receptor (8, 9).”
BackgroundFujii, S., Goto, A., & Shimizu, K. (2009) · Blood · doi:10.1182/blood-2008-08-176446 · Cited by 52
Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D. F., Morisot, S., Civin, C. I., Wayne, A. S., Levine, B. L., & Mackall, C. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820d2a21 · Cited by 51
“However, at least one report demonstrated that activated NK cells lyse KIR ligand expressing targets[31] and over-expression of ligands for NK activating receptors can induce tumor rejection in the presence of KIR ligands[32,33], consistent with a model wherein a threshold level of activating signals can overcome inhi…”
NKG2D Blockade Inhibits Poly(I:C)-Triggered Fetal Loss in Wild Type but Not in IL-10−/− Mice
Thaxton, J. E., Nevers, T., Lippe, E. O., Blois, S. M., Saito, S., & Sharma, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203488 · Cited by 50
“The NKG2D activating receptor interacts with the minor histocompatibility Ag ligands, the retinoic acid early inducible-1 (Rae1) family members, and the heat shock 60 (H60) in mice (32, 40).”
BackgroundFriedman, J., Morisada, M. V., Sun, L., Moore, E. C., Padget, M. R., Hodge, J. W., Schlom, J., Gameiro, S. R., & Allen, C. T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0374-2 · Cited by 49
“Here, we demonstrated that WEE1 kinase inhibition also sensitized murine and human cancer cells to granzyme B-dependent NK killing independent of MHC class I, PD-L1 or NKG2D ligand expression [29, 30], suggesting that inhibition of cell cycle checkpoint activation may be a more universal approach to sensitizing tumor…”
BackgroundThe NKG2D axis: an emerging target in cancer immunotherapy
Lazarova, M., & Steinle, A. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1580693 · Cited by 47
Optimal treatment strategies for delayed cancer-immune system with multiple therapeutic approach
Das, P., Das, S., Upadhyay, R. K., & Das, P. (2020) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2020.109806 · Cited by 50
Role of gammadelta T lymphocytes in tumor defense
Zocchi, M. R., & Poggi, A. D. (2004) · Frontiers in bioscience · doi:10.2741/1419 · Cited by 49
Huergo-Zapico, L., González, A. P., Contesti, J., González, E., López‐Soto, A., Fernández-Guizán, A., Acebes‐Huerta, A., Toyos, J. R. D. L., López‐Larrea, C., Groh, V., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1195-z · Cited by 55
Westwood, J. A., Kelly, J. M., Tanner, J. E., Kershaw, M. H., Smyth, M. J., & Hayakawa, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.757 · Cited by 56
“NKG2D plays a key role in immune responses, including those against tumor (15, 16).”
BackgroundDNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor
Zhou, H., Luo, Y., Lo, J., Kaplan, C. D., Mizutani, M., Mizutani, N., Lee, J.-D., Primus, F. J., Becker, J. C., Xiang, R., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502208102 · Cited by 55
Hypoxia-mediated immune evasion of pancreatic carcinoma cells
Lu, Y., Hu, J., Sun, W., Duan, X., & Chen, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3144 · Cited by 50
Busche, A., Goldmann, T., Naumann, U., Steinle, A., & Brandau, S. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.135 · Cited by 51
“Here overexpression of RAE-1 has been demonstrated to inhibit tumor growth (Diefenbach et al ., 2001), but there exists controversy concerning the generation of T cell-mediated immunity (Cerwenka et al ., 2001).”
Zhang, J., Xu, Z., Zhou, X., Zhang, H., Yang, N., Wu, Y., Chen, Y., Yang, G.-S., & Ren, T. (2014) · PubMed · Cited by 48
Geldhof, A. B., Ginderachter, J. A. V., Liu, Y., Noël, W., Raes, G., & BAETSELIER, P. D. (2002) · Blood · doi:10.1182/blood-2001-11-0106 · Cited by 55
“Rae-1, unpublished observation) for the recently identified stimulatory lectin-like NKG2D receptor that is expressed by NK cells and activated macrophages in mice.(1,63-64) Interaction between NKG2D and ligands (Rae-1,”
BackgroundDeguine, J., Bréart, B., Lemaître, F., & Bousso, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202065 · Cited by 51
“Because NKG2D ligands alone can induce tumor cell rejection (9), we measured EG7 elimination at an early time point using a second tumor cell line that does not express NKG2D ligands or CD4 as an internal control.”
BackgroundLu, S., Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Li, Z., & Wu, J. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0845 · Cited by 47
“In experimental animal models, ligand-induced activation of NKG2D has been demonstrated very effective in controlling tumor initiation and progression through activating natural killer (NK) and costimulating effector T cells, including cytotoxic T lymphocytes and NKT cells (5, 6).”
BackgroundGenomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer
Coulouarn, C., Factor, V. M., Conner, E. A., & Thorgeirsson, S. S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr133 · Cited by 47
Involvement of Activating NK Cell Receptors and Their Modulation in Pathogen Immunity
Marras, F., Bozzano, F. M., & Maria, A. D. (2011) · BioMed Research International · doi:10.1155/2011/152430 · Cited by 51
“Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2011, Article ID 152430, 11 pages doi:10.1155/2011/152430”
BackgroundInfluentialSohlberg, E., Pfefferle, A., Andersson, S., Baumann, B. C., Hellström‐Lindberg, E., & Malmberg, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6213 · Cited by 50
“Stressed and transformed cells upregulate MHC class I chain related proteins A and B (MICA/B) and UL16-binding proteins (ULBPs) (NKG2DL) that interact with NKG2D, one of the major NK-cell activating receptors involved in tumor cell recognition [12].”
BackgroundTripathy, S. K., Smith, H. R. C., Holroyd, E. A., Pingel, J. T., & Yokoyama, W. M. (2005) · Journal of Virology · doi:10.1128/jvi.80.1.545-550.2006 · Cited by 47
Osaki, T., Saito, H., Yoshikawa, T., Matsumoto, S., Tatebe, S., Tsujitani, S., & Ikeguchi, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1454 · Cited by 49
Uncoupling between Immunological Synapse Formation and Functional Outcome in Human γδ T Lymphocytes
Favier, B., Espinosa, É., Tabiasco, J., Santos, C. D., Bonneville, M., Valitutti, S., & Fournié, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5027 · Cited by 47
Natural killer cell-based therapies
Romagné, F., & Vivier, É. (2011) · F1000 Medicine Reports · doi:10.3410/m3-9 · Cited by 46
“In mouse models, the expression of NK-stimulatory NKG2D ligands not only induces short-term rejection of tumors, but also induces a protective adaptive immune response [5].”
BackgroundBurke, B., Eden, C., Pérez, C., Belshoff, A. C., Hart, S., Plaza-Rojas, L., Reyes, M. D., Prajapati, K., Voelkel‐Johnson, C., Henry, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00699 · Cited by 48
“Raulet groups where genetically-driven expression of NKG2D ligands in tumors was sufficient to cause tumor rejection (49, 50).”
BackgroundBcl10 Plays a Divergent Role in NK Cell-Mediated Cytotoxicity and Cytokine Generation
Malarkannan, S., Regunathan, J., Chu, H., Kutleša, S., Chen, Y., Zeng, H., Wen, R., & Wang, D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3752 · Cited by 46
Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model
Kim, J.-E., Cho, H.-S., Yang, H.-S., Jung, D.-J., Hong, S.-W., Hung, C.-F., Lee, W. J., & Kim, D. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.12.010 · Cited by 46
Bouaziz, J., Ortonne, N., Giustiniani, J., Schiavon, V., Huet, D., Bagot, M., & Bensussan, A. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23914.x · Cited by 51
Natural killer and γδ T cells in haematological malignancies: enhancing the immune effectors
Rey, J., Veuillen, C., Vey, N., Bouabdallah, R., & Olive, D. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.04.005 · Cited by 53
Kitajima, M., Abe, T., Miyano‐Kurosaki, N., Taniguchi, M., Nakayama, T., & Takaku, H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300364 · Cited by 46
Tran, J. N. S. N., & Kung, S. K. P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300184 · Cited by 46
Xu, X., Rao, G., Gaffud, M. J., Ding, H. G., Maki, G., Klingemann, H.-G., Groh, V., Spies, T. A., Caillat‐Zucman, S., Gattuso, P., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0492 · Cited by 46
Chiang, E. Y., Henson, M., & Stroynowski, I. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2200 · Cited by 49
“A precedent for different activation pathways being inhibited differentially by class I has been reported for RMA vs RAE-1-transfected RMA cells (60).”
BackgroundBCR/ABL Promotes Dendritic Cell–Mediated Natural Killer Cell Activation
Terme, M., Borg, C., Guilhot, F., Masurier, C., Flament, C., Wagner, E. F., Caillat‐Zucman, S., Bernheim, A., Turhan, A. G., Caignard, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2675 · Cited by 46
“Ectopic expression of ligands for NK cell activating receptors on tumor cells allowed NK cell– mediated tumor rejection in various mouse tumor models in vivo (41).”
BackgroundNatural killer cell–based immunotherapy for cancer
Ma, S., Yu, J., & Caligiuri, M. A. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf036 · Cited by 47
Davis, D. A., Shrestha, P., Aisabor, A. I., Stream, A., Galli, V., Pise-Masison, C. A., Tagawa, T., Ziegelbauer, J. M., Franchini, G., & Yarchoan, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546544 · Cited by 46
“occur even in the presence of normal MHC-I expression, especially when activating receptors in the NK cells are engaged by their activating ligands.(58,59) Also, there is evidence that NK killing of cells infected by another herpesvirus, cytomegalo-”
BackgroundMärklin, M., Hagelstein, I., Koerner, S., Rothfelder, K., Pflügler, M., Schumacher, A., Große‐Hovest, L., Jung, G., & Salih, H. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0606-0 · Cited by 48
Ogbomo, H., Michaelis, M., Klassert, D., Doerr, H. W., & Cinatl, J. J. (2008) · Neoplasia · doi:10.1593/neo.08972 · Cited by 45
“Recent experiments demonstrated that NKG2D/NKG2D ligand system stimulates immune surveillance of tumors [50–52].”
BackgroundManipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response
Jonjić, S. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00085 · Cited by 50
“The expression of NKG2D ligands makes tumors susceptible to killing by NK cells in vitro and is associated with a decreased tumor progression and a decreased capacity to form metastases in vivo (Bauer et al., 1999; Cerwenka et al., 2000, 2001; Diefenbach et al., 2000, 2001).”
BackgroundNeonatal Natural Killer Cell Function: Relevance to Antiviral Immune Defense
Lee, Y.-C., & Lin, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/427696 · Cited by 46
Wang, X., Lundgren, A. D., Singh, P., Goodlett, D. R., Plymate, S. R., & Wu, J. D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.062 · Cited by 49
“Ligand-induced activation of NKG2D on NK cells and CTLs has been demonstrated to be very effective in tumor destruction in experimental animal models [10,11].”
BackgroundRegulation of the expression of the liver cancer susceptibility gene MICA by microRNAs
Kishikawa, T., Otsuka, M., Yoshikawa, T., Ohno, M., Takata, A., Shibata, C., Kondo, Y., Akanuma, M., Yoshida, H., & Koike, K. (2013) · Scientific Reports · doi:10.1038/srep02739 · Cited by 40
Romero, A. I., Chaput, N., Poirier-Colame, V., Rusakiewicz, S., Jacquelot, N., Chaba, K., Mortier, E., Jacques, Y., Caillat-Zucman, S., Flament, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1186 · Cited by 42
The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right
Park, D. S., Robertson‐Tessi, M., Luddy, K. A., Maini, P. K., Bonsall, M. B., Gatenby, R. A., & Anderson, A. R. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3712 · Cited by 43
“10 1 day based on the potency of CTLs in preventing tumor growth when stimulated by 215 multiple types of tumor antigen [34].”
BackgroundExploring the dynamics of a tumor-immune interplay with time delay
Sardar, M., Khajanchi, S., Biswas, S., Abdelwahab, S. F., & Nisar, K. S. (2021) · Alexandria Engineering Journal · doi:10.1016/j.aej.2021.03.041 · Cited by 43
Barber, M. A., Zhang, T., Gagne, B. A., & Sentman, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6140 · Cited by 45
“RMA tumors grow in a similar manner in the presence or absence of NK cells, which suggests that NK cells may not play a role in responses to these tumors (21, 22).”
BackgroundNatural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Ruggeri, L., Mancusi, A., Burchielli, E., Perruccio, K., Aversa, F., Martelli, M., & Velardi, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.007 · Cited by 49
Bourquin, C., Schmidt, L., Lanz, A.-L., Storch, B., Wurzenberger, C., Anz, D., Sandholzer, N., Mocikat, R., Berger, M., Poeck, H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901594 · Cited by 43
“Because both MHC-negative and MHC-positive tumor cells can thus be eliminated, the combined activation of CTL and NK cells by RNA-based therapies may help prevent tumor immune escape (59).”
BackgroundDu, W., Chen, C., Sun, P., Zhang, S., Zhang, J., Zhang, X., Liu, Y., Zhang, R., Yan, C., Fan, C., et al. (2020) · Nanoscale · doi:10.1039/c9nr09835f · Cited by 42
Alajez, N. M., Schmielau, J., Alter, M. D., Cascio, M., & Finn, O. J. (2005) · Blood · doi:10.1182/blood-2004-10-3848 · Cited by 42
Dhanji, S., Teh, S.-J., Oble, D. A., Priatel, J. J., & Teh, H. (2004) · Blood · doi:10.1182/blood-2004-01-0150 · Cited by 44
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.